You are here: Industry Insights > Clover

News List

Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate prnasia
July 06, 2021
Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, today announced the completion of ...
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover's COVID-19 Vaccine for the COVAX Facility prnasia
June 30, 2021
Clover today announced an advance purchase agreement (APA) with Gavi, the Vaccine Alliance, to provide up to 414 million doses of its protein-based COVID-19 vaccine candidate for procurement through the COVAX Facility.
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate prnasia
June 30, 2021
Clover and Dynavax today announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
First Participants Dosed in Adjuvanted S-Trimer COVID-19 Vaccine Candidate Trial americanpharmaceuticalreview
April 01, 2021
Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 ...
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate prnewswire
March 25, 2021
Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics such as vaccines and therapeutics for the world's most debilitating diseases, and Dynavax Technologies Corporation, a biopharmaceutical ...
Healthcare industry reported 85 deals worth $30 billion in Feb 2021 expresspharma
March 08, 2021
In February 2021, the healthcare industry reported 85 deals worth $30 billion as compared to last 12-month average (February 2020 to January 2021) of 88 deals worth $17.3 billion.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet prnasia
February 01, 2021
Clover Biopharmaceuticals today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its protein-based adjuvanted S-Trimer COVID-19 vaccine candidates was published in the peer-reviewed journal, The Lancet.
Forage Genetics conducts a field trial for GM white clover biospectrumasia
August 24, 2017
The clover contains a gene that’s important for the company’s efforts to engineer condensed tannins into alfalfa forage.